Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Staying on TRK: Addressing Clinical Challenges and Improving Outcomes in NTRK Fusion Positive Cancers
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: July 7, 2021 Expiration: July 6, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group
George D. Demetri, MD
Program Director
Alexander Drilon, MD
Theodore Laetsch, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Implement TRK inhibitor therapy for appropriate patients with cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received consulting fees from AbbVie, AdaptImmune, Bayer, Bessor, Blueprint Medicines, Caprion/HistoGeneX, Caris Life Sciences, Champions Biotechnology, Daiichi Sankyo, EMD Serono, Epizyme, Erasca, G1 Therapeutics, GlaxoSmithKline, Icon, Ignyta, Janssen, Loxo Oncology, Merrimack, Mirati, MJ Hennessey, Novartis, PharmaMar, Pfizer, Polaris, Relay, Roche/Genentech, Sanofi, Translate BIO, WCG/Arsenal Capital, and ZioPharm and royalties paid to his institution from Novartis.

Faculty

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, EMD Serono, Exelixis, Helsinn, Hengrui, Ignyta/Genentech/Roche, Liberum, Loxo/Bayer/Lilly, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Pfizer, Remedica, Repare RX, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Exelixis, Foundation Medicine, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and other financial support or material from Boehringer Ingelheim, Merck, Merus, and Puma.
Theodore Laetsch, MD

Associate Professor
Division of Oncology
Department of Pediatrics
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Theodore Laetsch, MD, has disclosed that he has received funds for research support from Bayer, Lilly, and Turning Point; consulting fees from Bayer, Cellectis, Deciphera, Jumo Health, Novartis, and Y-mAbs Therapeutics; and other financial or material support from Bayer.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for physicians and other healthcare providers who treat patients with cancer.

Goal

The goal of this program is to improve the knowledge and competence of learners to test for NTRK gene fusion and integrate TRK inhibitors into the treatment of patients with cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 07, 2021, through July 06, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Staying on TRK: Addressing Clinical Challenges and Improving Outcomes in NTRK Fusion Positive Cancers
  • CME

Loading...
In this on-demand webcast from a live symposium, expert faculty discuss the latest guidance and clinical data in the diagnosis and treatment of patients with NTRK fusion‑positive cancers.
George D. Demetri, MD
Program Director
Alexander Drilon, MD
Theodore Laetsch, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: July 7, 2021 Expiration: July 6, 2022

Related Content

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Results from phase III ATLANTIS trial of lurbinectedin plus doxorubicin in patients with relapsed small-cell lung cancer (SCLC), from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021

CheckMate 9LA analysis of nivolumab plus ipilimumab plus chemotherapy in advanced NSCLC with brain metastases, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue